Atossa Therapeutics, Inc.
Equity & Debt
| Period | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| Mar 2022 | — | $135.2M | $131.5M |
| Jun 2022 | — | $130.3M | $125.5M |
| Sep 2022 | — | $123.9M | $117.4M |
| Dec 2022 | — | $118.0M | $110.9M |
| Mar 2023 | — | $113.3M | $103.9M |
| Jun 2023 | — | $104.9M | $99.4M |
| Sep 2023 | — | $98.3M | $94.0M |
| Dec 2023 | — | $91.0M | $88.5M |
| Mar 2024 | — | $85.8M | $84.0M |
| Jun 2024 | — | $80.2M | $79.5M |
| Sep 2024 | — | $73.7M | $74.8M |
| Dec 2024 | — | $71.5M | $71.1M |
| Mar 2025 | — | $65.3M | $65.1M |
| Jun 2025 | — | $57.7M | $57.9M |
| Sep 2025 | — | $49.8M | $51.8M |
| Dec 2025 | — | $39.4M | $41.3M |
| Mar 2026 | — | $30.5M | $31.7M |
| Jun 2026 | — | $26.8M | $26.1M |